Dr. Chiara Lanzuolo
Conference room Querzoli - LENS - via Nello Carrara 1 - Sesto Fiorentino (Florence)
Published on-line at 11:34:47 AM on Thursday, June 28th, 2012
Epigenetic signatures in cancer
The epigenetic silencing of genes during embryonic development allows for the terminal differentiation that is essential for complex body plans.
Complex higher-order structures found in the cell nucleus serve to compact areas of chromatin so that it is no longer transcriptionally active. One such group of structures, called Polycomb bodies, are composed of Polycomb group (PcG) gene products, Polycomb response elements (PREs), and specific gene promoters that interact to regulate the suppression of key developmental genes by altering the physical conformation of chromatin into loops (Lanzuolo et al., 2007).
In humans, PcG proteins are key epigenetic regulators of chromatin architecture in the nucleus that act as transcriptional repressors. PcG proteins regulate large numbers of target genes, primarily those involved in differentiation and development (Richly et al., 2011). In the nucleus, PcG proteins are organized as microscopically visible foci called PcG bodies. Recently, it has been shown that PcG bodies are highly dynamic during embryogenesis, suggesting a correlation between the flexibility of chromatin structures and the potential for cell differentiation (Cheutin and Cavalli, 2012).
These complexes have also been shown to be upregulated in several human cancers, including breast, bladder, colon and prostate cancers. PcG proteins function to suppress the transcription of tumor suppressor genes, and their overexpression leads to uncontrolled proliferation, malignant transformation and changes in cancer progression.[video=720 538]20120703_lanzuolo[/video]
For further informations, please contact Dr. Blaine Bisel.
Internal and Reserved Area
Elenco Siti Tematici